Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Karnon

Showing results (11-20 of 216) with videos related to

Pageof 22
Sort By:
Pharmacoeconomics|June 24, 2015
Cost-Value Analysis and the SAVE: A Work in Progress, But an Option for Localised Decision Making?Jonathan Karnon, Andrew Partington
Applied Health Economics and Health Policy|October 25, 2023
Adding Value to CHEERS: New Reporting Standards for Value of Information AnalysesJonathan Karnon, Clarabelle Pham
Applied Health Economics and Health Policy|February 6, 2020
Should Health Economic Evaluations Undertaken from a Societal Perspective Include Net Government Spending Multiplier Effects?Jonathan Karnon, Brita Pekarsky
BMJ Open|May 8, 2019
in-DEPtH framework: evidence-<u>in</u>formed, co-creation framework for the <u>D</u>esign, <u>E</u>valuation and <u>P</u>rocuremen<u>t</u> of <u>H</u>ealth servicesKenneth Lo, Jonathan Karnon
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 20, 2014
A patient-level calibration framework for evaluating surveillance strategies: a case study of mammographic follow-up after early breast cancerTaryn Bessen, Jonathan Karnon
Pharmacoeconomics|December 15, 2010
Calibrating models in economic evaluation: a comparison of alternative measures of goodness of fit, parameter search strategies and convergence criteriaJonathan Karnon, Tazio Vanni
Pharmacoeconomics|March 13, 2002
Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluationJonathan Karnon, Jackie Brown,
Health Policy and Planning|March 28, 2016
Option B+ for the prevention of mother-to-child transmission of HIV infection in developing countries: a review of published cost-effectiveness analysesJonathan Karnon, Nneka Orji
International Journal of Health Policy and Management|July 3, 2020
It's Not the Model, It's the Way You Use It: Exploratory Early Health Economics Amid Complexity Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling"Andrew Partington, Jonathan Karnon
Archives of Clinical and Biomedical Research|April 3, 2023
Strict Lockdown versus Flexible Social Distance Strategy for COVID-19 Disease: a Cost-Effectiveness AnalysisBen W Mol, Jonathan Karnon
Pageof 22

Showing results (11-20 of 216) with videos related to

Sort By:
Pageof 22
Pharmacoeconomics|June 24, 2015
Cost-Value Analysis and the SAVE: A Work in Progress, But an Option for Localised Decision Making?Jonathan Karnon, Andrew Partington
Applied Health Economics and Health Policy|October 25, 2023
Adding Value to CHEERS: New Reporting Standards for Value of Information AnalysesJonathan Karnon, Clarabelle Pham
Applied Health Economics and Health Policy|February 6, 2020
Should Health Economic Evaluations Undertaken from a Societal Perspective Include Net Government Spending Multiplier Effects?Jonathan Karnon, Brita Pekarsky
BMJ Open|May 8, 2019
in-DEPtH framework: evidence-<u>in</u>formed, co-creation framework for the <u>D</u>esign, <u>E</u>valuation and <u>P</u>rocuremen<u>t</u> of <u>H</u>ealth servicesKenneth Lo, Jonathan Karnon
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 20, 2014
A patient-level calibration framework for evaluating surveillance strategies: a case study of mammographic follow-up after early breast cancerTaryn Bessen, Jonathan Karnon
Pharmacoeconomics|December 15, 2010
Calibrating models in economic evaluation: a comparison of alternative measures of goodness of fit, parameter search strategies and convergence criteriaJonathan Karnon, Tazio Vanni
Pharmacoeconomics|March 13, 2002
Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluationJonathan Karnon, Jackie Brown,
Health Policy and Planning|March 28, 2016
Option B+ for the prevention of mother-to-child transmission of HIV infection in developing countries: a review of published cost-effectiveness analysesJonathan Karnon, Nneka Orji
International Journal of Health Policy and Management|July 3, 2020
It's Not the Model, It's the Way You Use It: Exploratory Early Health Economics Amid Complexity Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling"Andrew Partington, Jonathan Karnon
Archives of Clinical and Biomedical Research|April 3, 2023
Strict Lockdown versus Flexible Social Distance Strategy for COVID-19 Disease: a Cost-Effectiveness AnalysisBen W Mol, Jonathan Karnon
Pageof 22